Bruce F. Wesson - 02 Jan 2024 Form 4 Insider Report for ACURA PHARMACEUTICALS, INC

Role: Director, Director Emeritus
Signature: /s/ Bruce Wesson
Issuer symbol: N/A
Transactions as of: 02 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Jan 2024, 15:20:14 UTC
Previous filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACUR	Common Stock	Options Exercise		+37,500	+4.7%		829,548	02 Jan 2024	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACUR	Restricted Stock Units (2021 Plan)	Options Exercise		-37,500	-75%		12,500	02 Jan 2024	Common Stock	37,500		Direct	F2, F4, F5, F6
transaction	ACUR	Restricted Stock Units (2021 Plan)	Disposed to Issuer		-12,500	-100%		0	02 Jan 2024	Common Stock	0		Direct	F2, F4, F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents exchange of restricted stock units.
F2	Par value of $.01 per share must be paid by Reporting Person upon exchange of Restricted Stock Units for stock
F3	Does not include Restricted Stock Units.
F4	1 - for - 1
F5	50,000 Restricted Stock Units were granted on January 3, 2023. 25% of Restricted Stock Units vested on the last day of each of March, June, and September 2023. Restricted Stock Units are being exchanged on a one for one basis for common stock, in each case upon payment of par value.
F6	N/A
F7	25% of the 50,000 Restricted Stock Units granted on January 3, 2023 did not vest and were forfeited due to the departure of the Director in September 2023.